Ross Muken Sells 9,838 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the transaction, the chief executive officer owned 670,651 shares in the company, valued at $3,500,798.22. This represents a 1.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ross Muken also recently made the following trade(s):

• On Monday, June 22nd, Ross Muken sold 422 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.38, for a total value of $2,270.36.
• On Monday, April 20th, Ross Muken sold 760 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total value of $3,952.00.
• On Tuesday, April 14th, Ross Muken sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $13,888.00.
• On Monday, April 13th, Ross Muken sold 4,442 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $21,143.92.
• On Friday, April 10th, Ross Muken sold 3,687 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.69, for a total value of $17,292.03.
• On Thursday, April 9th, Ross Muken sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Ross Muken sold 2,786 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,484.24.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $5.51 on Thursday. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.30. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The company has a 50-day moving average of $5.15 and a 200-day moving average of $4.97. The firm has a market cap of $462.23 million, a price-to-earnings ratio of -10.60 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million.

Analyst Ratings Changes

Several research analysts have issued reports on the company. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.50.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were reported as pre-planned Rule 10b5-1 transactions tied to equity vesting and tax withholding, suggesting they may be administrative rather than a reflection of weakening business fundamentals.
• Neutral Sentiment: Several insiders sold shares in the same short period, including the chairman, CEO, CFO, and other executives, which keeps investor focus on insider activity. Article Title
• Negative Sentiment: A heavy run of insider selling can still pressure shares near term because some investors may interpret it as reduced confidence or increased stock supply.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the fourth quarter worth $49,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS during the third quarter valued at $49,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the first quarter valued at $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in SOPHiA GENETICS in the 4th quarter worth about $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.